TORONTO, Jan. 10, 2018 /CNW/ - Nuuvera Inc. ("Nuuvera")
(TSXV:NUU) is very pleased to announce that it is establishing a
state-of-the-art laboratory in Saint
John, New Brunswick that will process, manufacture and
distribute pharmaceutical-grade medical marijuana derivative
products.
Nuuvera has purchased a property in Saint John to accommodate its facility. The
building will be retro-fit immediately upon the issuance of
necessary zoning permits and licenses. This will
be Nuuvera's second lab facility in Canada and will create new skilled jobs for
Saint John.
An industry leader in global medical
cannabis, Nuuvera operates in many countries around the
world.
"Our extensive international operations make
us uniquely positioned to understand global supply and demand
pressures before they become highly problematic which ensures we
can serve patients' needs. We are committed to delivering premium
quality, reliable and consistent supply at a competitive price,"
said Nuuvera CEO, Lorne Abony.
The Saint John
laboratory will produce cannabis products for
New Brunswick, for Canada, and for the rapidly growing global
market that Nuuvera services.
Abony continued, "Premier Brian
Gallant has been a true thought leader and
incredibly proactive in understanding the importance and
potential of the cannabis industry for New Brunswick and
Canada specifically, and for the
world generally. We are delighted to have chosen
Saint John as the location for
this very important lab and to have worked closely with
Opportunities New Brunswick to make this facility happen.
The cannabis industry represents a tremendous opportunity for
New Brunswick to develop a
world-class ecosystem to support premium quality cultivation,
production and research and development."
For more information on Nuuvera, please visit:
www.nuuvera.com
About Nuuvera
Nuuvera is a global cannabis company founded on Canadian
principles, and built with the whole world in mind. Nuuvera is
currently working with partners in Germany, Israel and Italy, and is exploring opportunities in
several other countries, to develop commercial production and
global distribution of medical grade cannabis in legalized markets.
Through its subsidiaries, ARA – Avanti Rx Analytics Inc. and Avalon
Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the
Narcotic Control Regulations and Office of Controlled Substances.
Nuuvera is currently in the final stages of the Health Canada
review process to become a Licensed Producer of medical marijuana
under the ACMPR, and has recently received its "letter to build"
approval.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
Nuuvera and its business. Often, but not always, forward-looking
statements can be identified by the use of words such as "plans",
"is expected", "expects", "scheduled", "intends", "contemplates",
"anticipates", "believes", "proposes" or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results "may", "could", "would", "might"
or "will" be taken, occur or be achieved. Such statements are based
on the current expectations of the management of Nuuvera. The
forward-looking events and circumstances discussed in this release
may not occur by certain specified dates or at all and could differ
materially as a result of known and unknown risk factors and
uncertainties affecting Nuuvera, including risks regarding the
cannabis industry, failure to obtain regulatory approvals, economic
factors, the equity markets generally and risks associated with
growth and competition. Although Nuuvera has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made Nuuvera undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
The TSX Venture Exchange has in no way passed upon the merits
of the transaction and has neither approved nor disapproved the
content of this press release.
SOURCE Nuuvera Inc.